Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

We recently published a list of 15 Best Dividend Stocks To Buy and Hold. In this article, we are going to take a look at ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

2025 EPS Guidance: $8.88 to $9.03. Merck & Co Inc (NYSE:MRK) achieved strong growth in 2024, driven by demand for its innovative portfolio, including KEYTRUDA and the successful launch of WINREVAIR.

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA Biosciences, the biotech has agreed to sell the deals to an investment ...

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best dividend stocks to buy and hold. In recent years, many investors have shifted their ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...